- Home
- ERAS vs SLDB Comparison
ERAS vs SLDB Comparison
Compare ERAS & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- SLDB
- Stock Information
- Founded
- ERAS 2018
- SLDB 2013
- Country
- ERAS United States
- SLDB United States
- Employees
- ERAS N/A
- SLDB N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- SLDB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ERAS Health Care
- SLDB Health Care
- Exchange
- ERAS Nasdaq
- SLDB Nasdaq
- Market Cap
- ERAS 439.7M
- SLDB 433.0M
- IPO Year
- ERAS 2021
- SLDB 2018
- Fundamental
- Price
- ERAS $1.71
- SLDB $5.41
- Analyst Decision
- ERAS Buy
- SLDB Strong Buy
- Analyst Count
- ERAS 6
- SLDB 10
- Target Price
- ERAS $3.83
- SLDB $15.00
- AVG Volume (30 Days)
- ERAS 964.1K
- SLDB 752.0K
- Earning Date
- ERAS 11-11-2025
- SLDB 11-05-2025
- Dividend Yield
- ERAS N/A
- SLDB N/A
- EPS Growth
- ERAS N/A
- SLDB N/A
- EPS
- ERAS N/A
- SLDB N/A
- Revenue
- ERAS N/A
- SLDB N/A
- Revenue This Year
- ERAS N/A
- SLDB N/A
- Revenue Next Year
- ERAS N/A
- SLDB N/A
- P/E Ratio
- ERAS N/A
- SLDB N/A
- Revenue Growth
- ERAS N/A
- SLDB N/A
- 52 Week Low
- ERAS $1.01
- SLDB $2.41
- 52 Week High
- ERAS $3.31
- SLDB $8.10
- Technical
- Relative Strength Index (RSI)
- ERAS 59.36
- SLDB 50.71
- Support Level
- ERAS $1.53
- SLDB N/A
- Resistance Level
- ERAS $1.69
- SLDB $5.50
- Average True Range (ATR)
- ERAS 0.10
- SLDB 0.28
- MACD
- ERAS 0.01
- SLDB -0.20
- Stochastic Oscillator
- ERAS 96.20
- SLDB 93.28
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.